Isaac Francis

Aave Labs has proposed a new Technical Asset Listing Framework designed to create a unified standard for evaluating and monitoring assets across Aave V3, Aave V4 and Aave Horizon.

Billionaire investor Mark Cuban said he sold roughly 80% of his Bitcoin holdings after concluding the cryptocurrency failed to perform as a hedge against geopolitical turmoil during the Iran war.

Stablecoins may settle trillions of dollars globally each year, but they still represent less than 5% of transaction volume within regulated US payments infrastructure, according to Reliant president David Simon.

Intercontinental Exchange chief executive Jeffrey Sprecher said the operator of the New York Stock Exchange is working with and learning from Hyperliquid as crypto perpetual futures continue to gain traction among traders.

US Treasury Secretary Scott Bessent said the US government has seized roughly $1 billion worth of cryptocurrency from Iran as part of its efforts to disrupt financial networks linked to the country.

Elmet Group (NASDAQ:ELMT) reported a 20.7% increase in first-quarter revenue, propelled by expanding volumes in its core aerospace, defense, and government end markets.

Best Buy (NYSE:BBY) announced that its Board of Directors has authorized the payment of a regular quarterly cash dividend of $0.96 per common share, maintaining the electronics retailer's commitment to its ongoing capital return program.

CollPlant Biotechnologies (NASDAQ:CLGN) initiated a formal review of its strategic alternatives after a sharp contraction in milestone revenue caused its first-quarter sales to drop to near-zero, forcing the company to slash its workforce by half.

Crypto.com has obtained a Stored Value Facilities licence in the United Arab Emirates and introduced new product features including SEI migration support and Bitcoin rewards for eligible Visa card users.

The U.S. Food and Drug Administration approved AstraZeneca's (NYSE:AZN) blockbusting immunotherapy Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, marking a major regulatory expansion for the company’s oncology franchise into earlier-stage disease.